Sponsored By

Let’s Talk Medtech spoke with Dave Hadley, Phd, Senior VP of Research & Development of Cardiac Insight, about the company and the exploding ECG market.

Omar Ford

May 26, 2021

1 Min Read
IMG_May262021at14708PM.jpg
spaxiax - stock.adobe.com

Cardiac Insight is seeing a major uptick in ECG screenings. The Seattle, WA-based company reported there was more than a 70% surge in sales of the Cardea 20/20 ECG in 1Q21.

Let’s Talk Medtech recently spoke with Dave Hadley, Phd, Senior VP of Research & Development. He is the inventor of Cardea 20/20, about the surge and recent interest in the ECG market. Dr. Hadley has more than 30 years of hands-on experience blending customer needs with information technology through research and development. 

Cardiac Insight was named a finalist for this year’s Medical Design Excellence Awards.

Click here to access the most recent episode of Let's Talk Medtech. 

 

 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like